Unique ID issued by UMIN | UMIN000004374 |
---|---|
Receipt number | R000005230 |
Scientific Title | Identification of serum markers mediating resistance to sunitinib in patients with renal cell carcinoma |
Date of disclosure of the study information | 2010/10/13 |
Last modified on | 2010/10/12 18:49:05 |
Identification of serum markers mediating resistance to sunitinib in patients with renal cell carcinoma
Identification of serum markers mediating resistance to sunitinib in patients with renal cell carcinoma
Identification of serum markers mediating resistance to sunitinib in patients with renal cell carcinoma
Identification of serum markers mediating resistance to sunitinib in patients with renal cell carcinoma
Japan |
renal cell carcinoma
Urology |
Malignancy
NO
The objective of this study is to identify serum markers associated with resistant phenotype to sunitinib in patients with metastatic RCC in order to develop the precise system for predicting the probability of the acquired resistant phenotype to sunitinib in patients with RCC during treatment with this agent.
Efficacy
 Before and during treatment with sunitinib, measure serum levels of several molecules (E-cadherin, N-cadherin, fibronectin, MMP-2, MMP-3, MMP-9, MT-MMP-1, TIMP-1, TIMP-2, clusterin, bFGF, uPA and uPAR), which have been shown to be regulated by activated p44/42 MAPK and Akt and to be involved in the acquisition of an EMT phenotype in our preliminary experiments, in patients with metastatic RCC by sandwich enzyme-linked immunosorbent assay (ELISA) kits.
Observational
20 | years-old | <= |
Not applicable |
Male and Female
Histologically confirmed metastatic RCC with a component of clear cell histology.
Presence of measurable disease; that is, at least 1 metastatic tumor mass that can be accurately measured in at least 1 dimension over 10 mm with conventional radiological modalities, such as computed tomography and magnetic resonance imaging.
Age of over 20 years.
ECOG performance status of 0 or 1.
Life expectancy of over 12 weeks
Prior use of sunitinib
Seizure disorder, evidence of brain metastases, spinal cord compression or carcinomatous meningitis.
Active bacterial, fungal or viral infection.
History of malignancy other than RCC except for those treated with curative intent with no evidence of disease for at least 2 years.
Other severe acute or chronic medical condition.
100
1st name | |
Middle name | |
Last name | Masato Fujisawa |
Kobe University Graduate school of Medicine
Department of Urology
7-5-1,Kusunoki-tyo,Kobe-city, Japan
1st name | |
Middle name | |
Last name |
Kobe University Graduate school of Medicine
Department of Urology
7-5-1,Kusunoki-tyo,Kobe-city, Japan
Kobe University Graduate school of Medicine
pfizer pharmacology
Profit organization
NO
2010 | Year | 10 | Month | 13 | Day |
Unpublished
Preinitiation
2010 | Year | 09 | Month | 10 | Day |
2010 | Year | 11 | Month | 01 | Day |
not finished
2010 | Year | 10 | Month | 12 | Day |
2010 | Year | 10 | Month | 12 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000005230